DK3365329T3 - Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge - Google Patents
Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge Download PDFInfo
- Publication number
- DK3365329T3 DK3365329T3 DK16794950.2T DK16794950T DK3365329T3 DK 3365329 T3 DK3365329 T3 DK 3365329T3 DK 16794950 T DK16794950 T DK 16794950T DK 3365329 T3 DK3365329 T3 DK 3365329T3
- Authority
- DK
- Denmark
- Prior art keywords
- nurr1
- sickness
- parkinson
- pathology
- symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92852A LU92852B1 (en) | 2015-10-20 | 2015-10-20 | NURR1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinsons disease |
| PCT/EP2016/075279 WO2017068070A1 (en) | 2015-10-20 | 2016-10-20 | Nurr1:rxr activating compounds for simultaneous treatment of symptoms and pathology of parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3365329T3 true DK3365329T3 (da) | 2022-07-04 |
Family
ID=54979898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16794950.2T DK3365329T3 (da) | 2015-10-20 | 2016-10-20 | Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10946019B2 (da) |
| EP (2) | EP4029857A1 (da) |
| DK (1) | DK3365329T3 (da) |
| LU (1) | LU92852B1 (da) |
| WO (1) | WO2017068070A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU92852B1 (en) | 2015-10-20 | 2017-05-02 | Athanasios Spathis | NURR1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinsons disease |
| KR20210038558A (ko) * | 2018-07-31 | 2021-04-07 | 오노 야꾸힝 고교 가부시키가이샤 | 벤젠 유도체 |
| US20230063230A1 (en) * | 2019-02-19 | 2023-03-02 | The Regents Of The University Of California | Nurr1 receptor modulators |
| JP7323913B2 (ja) * | 2019-04-12 | 2023-08-09 | 国立大学法人 筑波大学 | 睡眠誘導剤である複素環化合物 |
| JP7384179B2 (ja) * | 2020-01-29 | 2023-11-21 | 小野薬品工業株式会社 | ベンゼン誘導体を含有する医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL129020C (da) * | 1964-12-15 | |||
| FR2244459A1 (en) * | 1973-09-20 | 1975-04-18 | Delalande Sa | 2-Arylamino-pyrimidines - useful as sedatives, antiinflammatory, anti-ulcer, vasodilating, anticholinergic and anti-broncho- constricting agents and diuretics |
| WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| US20060293343A1 (en) * | 2005-05-18 | 2006-12-28 | Asahi Kasei Pharma Corporation | Pyrimidine derivatives |
| WO2007048065A2 (en) * | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| US8865723B2 (en) * | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| LU92852B1 (en) | 2015-10-20 | 2017-05-02 | Athanasios Spathis | NURR1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinsons disease |
-
2015
- 2015-10-20 LU LU92852A patent/LU92852B1/en active IP Right Grant
-
2016
- 2016-10-20 EP EP22157178.9A patent/EP4029857A1/en not_active Withdrawn
- 2016-10-20 EP EP16794950.2A patent/EP3365329B1/en active Active
- 2016-10-20 US US15/770,162 patent/US10946019B2/en active Active
- 2016-10-20 DK DK16794950.2T patent/DK3365329T3/da active
- 2016-10-20 WO PCT/EP2016/075279 patent/WO2017068070A1/en active Application Filing
-
2020
- 2020-12-30 US US17/137,629 patent/US20210186975A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210186975A1 (en) | 2021-06-24 |
| EP4029857A1 (en) | 2022-07-20 |
| WO2017068070A1 (en) | 2017-04-27 |
| EP3365329B1 (en) | 2022-03-30 |
| LU92852B1 (en) | 2017-05-02 |
| US20180311243A1 (en) | 2018-11-01 |
| EP3365329A1 (en) | 2018-08-29 |
| US10946019B2 (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| MA45192A (fr) | Traitement d'association | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3360508T3 (da) | Hjælpeanordning til dental behandling | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3789501T3 (da) | Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3347016T3 (da) | Diagnosticering og behandling af angstlidelse | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3365329T3 (da) | Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge | |
| DK3484423T3 (da) | Anordning til hypertermisk behandling af kløe | |
| DK3386523T3 (da) | Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme | |
| DK3405215T3 (da) | Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser | |
| DK3119911T3 (da) | Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter | |
| DK3224354T3 (da) | Manipulerede iminreductaser og fremgangsmåder til den reduktive aminering af keton- og aminforbindelser | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3068793T3 (da) | Manipulerede iminreductaser og fremgangsmåder til den reduktive aminering af keton- og aminforbindelser |